RIEDER v. ASTRAZENECA PHARMACEUTICALS LP

CourtDistrict Court, D. New Jersey
DecidedJune 27, 2022
Docket2:19-cv-00850
StatusUnknown

This text of RIEDER v. ASTRAZENECA PHARMACEUTICALS LP (RIEDER v. ASTRAZENECA PHARMACEUTICALS LP) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
RIEDER v. ASTRAZENECA PHARMACEUTICALS LP, (D.N.J. 2022).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

IN RE: PROTON-PUMP INHIBITOR PRODUCTS LIABILITY LITIGATION 2:17-MD-2789 (CCC) (LDW) (MDL 2789) This Document Relates to: Judge Claire C. Cecchi Rieder v. AstraZeneca Pharmaceuticals LP, 2:19-cv-00850 REPORT AND RECOMMENDATION OF SPECIAL MASTER ELLEN REISMAN REGARDING DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT ON STATUTE OF LIMITATION GROUNDS Plaintiff James Rieder is an Ohio resident who took prescription Nexium sold by Defendants AstraZeneca Pharmaceuticals LP, AstraZeneca LP, and Merck Sharp & Dohme Corporation (collectively, “Defendants”) from 2002 until early 2015.1 Nexium is a proton pump inhibitor (“PPI”) prescribed for patients with

gastroesophageal reflux disease (“GERD”). In October 2014, Plaintiff Rieder was

1 PSC’s Br. Opposing Defs.’ Mots. for Summ. J. on Failure to Warn Preemption, Ex. 283 at 138:12-18 [hereinafter “Rieder Dep.”] No. 2:17-md-2789, ECF No. 731-37. diagnosed with chronic kidney disease (“CKD”).2 He filed this lawsuit directly in this MDL on January 21, 2019.3

Defendants argue that Plaintiff Rieder’s claims are barred by Ohio’s two-year product liability statute of limitations.4 Defendants identify three possible dates on which Plaintiff Rieder’s cause of action accrued under Ohio law and triggered the running of the limitations period.5 Defendants first assert that Plaintiff Rieder’s

CKD diagnosis in October 2014 triggered the statute of limitations.6 In the alternative, they argue that if the limitations period did not begin to run in October 2014, it started to run in 2015 when Plaintiff Rieder stopped taking Nexium.7

Finally, they argue that, even if the limitations period did not begin to run on these earlier dates, it began to run when Plaintiff Rieder retained counsel in September 2016 prior to filing this lawsuit.8

The Plaintiffs’ Steering Committee (“PSC”), on behalf of Plaintiff Rieder, opposed the motion, arguing that the undisputed material facts do not establish, as a

2 PSC’s Suppl. Statement of Material Facts in Opp’n to Defs.’ Am. Mot. for Summ. J. as to Pl. James Rieder on Statue of Limitation Grounds 6, No. 2:17-md-2789, ECF No. 757-1. 3 Rieder Compl. ECF No. 1. 4 Defs.’ Am. Mem. of Law in Supp. of Mot. for Summ. J. as to Pl. James Rieder on Statute of Limitations Grounds 1, ECF No. 44 [hereinafter Defs.’ Summ. J. Mem.]. 5 Id. at 2-3. 6 Id. at 2. 7 Id. at 2-3. 8 Id. at 3-4. matter of law, that the Ohio statute of limitations ran prior to the filing of this lawsuit. The PSC argues that the record with respect to Defendants’ first two proposed

triggers, Plaintiff Rieder’s 2014 CKD diagnosis and his 2015 decision to stop using Nexium, is insufficient to establish as a matter of undisputed material fact that Plaintiff Rieder knew or should have known in the exercise of reasonable diligence that his CKD was related to his consumption of Nexium.9 It also argues that his

retention of counsel in 2016 is insufficient as a matter of law to trigger the statute of limitations, and that even if it were, his inclusion in the parties’ Tolling Agreement on July 31, 2018, stayed the running of the limitations period until after Plaintiff

Rieder filed this lawsuit.10 After reviewing the briefing and hearing oral argument on April 5, 2022,11 I recommend that Defendants’ motion be denied. With respect to the first two

potential trigger dates in 2014 and 2015, there are disputed issues of material fact that a jury must decide at trial in order to determine whether this lawsuit is time- barred. Defendants’ motion as to the third potential date of 2016 also fails as retention of counsel is insufficient to trigger the statute of limitations under Ohio

9 PSC’s Resp. to Defs.’ Am. Mot. for Summ. J. as to Pl. James Rieder on Statute of Limitations Grounds 12-19, No. 2:17-md-2789, ECF No. 716 [hereinafter PSC’s Summ. J. Opp’n Mem. in Rieder]. 10 See id. at 5-9; Stipulation Regarding Tolling of the Statute of Limitations, No. 2:17-md-2789, ECF No. 232; PSC’s Summ. J. Opp’n Mem. in Rieder, Ex. 6, Row 6,028, No. 2:17-md-2789, ECF No. 716-9. 11 Oral Args., Apr. 5, 2022, attached hereto in pertinent part as Ex. 1. law. In any event, the stay of the tolling period under the Tolling Agreement would make this lawsuit timely, even if the limitations period had begun to run in

September 2016. I. LEGAL STANDARD “Summary judgment is appropriate only where . . . there is no genuine issue

as to any material fact and . . . the moving party is entitled to judgment as a matter of law.”12 The evidence of the non-moving party is to be trusted and all inferences shall be drawn in its favor.13 The moving party bears the burden “of stating the basis for its motion and identifying those portions of the record that demonstrate the

absence of a genuine issue of material fact.”14 If the moving party meets this burden, the non-moving party “must set forth specific facts and present affirmative evidence demonstrating that there is a genuine issue for trial” and the non-moving party “may not ‘rest upon mere allegation[s] or denials of [his] pleading[.]”15 For a court to

12 Melrose Inc. v. Pittsburgh, 613 F.3d 380, 387 (3d Cir. 2010) (citing Ruehl v. Viacom, Inc., 500 F.3d 375, 380 n.6 (3d Cir. 2007)). 13 Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 254 (1986). 14 See Alley v. MTD Prods. Inc., No. 3:17-cv-3, 2017 U.S. Dist. LEXIS 208742, at *5 (W.D. Pa. Dec. 20, 2017) (citing Celotex Corp. v. Catrett, 477 U.S. 317, 323 (1986)). 15 Denson v. Atl. Cnty. Dep’t of Pub. Safety, No. 13-5315, 2016 U.S. Dist. LEXIS 132181, at *11 (D.N.J. Sept. 27, 2016) (citations omitted). consider an issue genuine, “there must be sufficient evidence . . . for a reasonable jury to find for the nonmovant.”16

II. DISCUSSION AND ANALYSIS A. Ohio’s Two-Year Statute Of Limitations For Product Liability And Personal Injury Claims The Parties agree that Ohio law applies to Plaintiff Rieder’s lawsuit because he is an Ohio resident who took Nexium and allegedly suffered injury while living in Ohio.17 I agree.18

Product liability claims and personal injury claims in Ohio are governed by the Ohio Product Liability Act (“OPLA”).19 Under OPLA, “an action based on a

16 Coolspring Stone Supply, Inc. v. Am. States Life Ins. Co., 10 F.3d 144, 148 (3d Cir. 1993). 17 See Defs.’ Summ. J. Mem. 11; PSC’s Summ. J. Opp’n Mem in Rieder 2 n.5. 18 Case Management Order (“CMO”) No. 7 states that “[f]iling an action directly in the MDL pursuant to this Order will not determine the applicable choice of law, including the choice of law for any of the claims in the action and for statute of limitations purposes.” CMO No. 7, at 6, No. 2:17-md-2789, ECF No. 112. The choice of law rules of Plaintiff Rieder’s home state, where he could have properly filed the case and had it transferred to the MDL, apply. See In re Valsartan, Losartan, & Irbesartan Prods. Liab. Litig., No. 1:19-md-2875, 2021 U.S. Dist. LEXIS 17728, at *52 (D.N.J. Jan. 29, 2021). Plaintiff Rieder’s home state is Ohio, where he lived at all times relevant to this litigation, ingested Nexium, and was diagnosed with and treated for CKD. Under Ohio choice of law rules, it is presumed that “the law of the place of the injury controls unless another jurisdiction has a more significant relationship to the lawsuit.” Morgan v. Biro Mfg.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Melrose, Inc. v. City of Pittsburgh
613 F.3d 380 (Third Circuit, 2010)
Ruehl v. Viacom, Inc.
500 F.3d 375 (Third Circuit, 2007)
Yacub v. Sandoz Pharmaceuticals Corp.
101 F. Supp. 2d 852 (S.D. Ohio, 1998)
Doty v. Fellhauer Electric, Inc.
888 N.E.2d 1138 (Ohio Court of Appeals, 2008)
Baxley v. Harley-Davidson Motor Co.
875 N.E.2d 989 (Ohio Court of Appeals, 2007)
O'Stricker v. Jim Walter Corp.
447 N.E.2d 727 (Ohio Supreme Court, 1983)
Morgan v. Biro Manufacturing Co.
474 N.E.2d 286 (Ohio Supreme Court, 1984)
Herr v. Robinson Memorial Hospital
550 N.E.2d 159 (Ohio Supreme Court, 1990)
Burgess v. Eli Lilly & Co.
609 N.E.2d 140 (Ohio Supreme Court, 1993)

Cite This Page — Counsel Stack

Bluebook (online)
RIEDER v. ASTRAZENECA PHARMACEUTICALS LP, Counsel Stack Legal Research, https://law.counselstack.com/opinion/rieder-v-astrazeneca-pharmaceuticals-lp-njd-2022.